Press Release

Sysmex Expands Sales of Its Reagents for Blood-based Amyloid β Testing to Europe

Sysmex Corporation (HQ: Kobe, Japan; President: Kaoru Asano) announces that, following their introduction in Japan and the United States, its reagents used for blood testing to identify Amyloid Beta (Aβ) accumulation in the brain—thought to be a leading cause of Alzheimer's disease, will be expanded to Europe starting January 2024. These reagents, the HISCL™ β-Amyloid 1-42 and 1-40 assay kits (“the assay kits”), have attained CE-IVD marking as of May 17, 2022. Going forward, Sysmex will continue to promote activities towards expanding our testing parameters, including the assay kits, accelerating the deployment of our immunochemistry testing business in Europe.

With dementia becoming a global social problem, Sysmex has been focusing its efforts on commercialization and market expansion for blood biomarkers that enable minimally invasive, simple, and rapid testing for the disease. As one such biomarker, the company has developed reagents for use with its HISCL-5000/HISCL-800 Automated Immunoassay System ("HISCL-Series”) in identifying the Aβ accumulation in the brain from a small amount of blood. In addition to launching the assay kits as in vitro diagnostic products in Japan in June 2023, Sysmex has started supplying them for the US LDT1 market in August 2023.
In Europe, since completing the declaration of conformity to the European IVD Directive (IVDD) for the assay kits in May 2022, Sysmex has been accumulating evidence through collaborative research with Key Opinion Leaders (KOLs). In order to expand its clinical application, the company has been working on regulatory compliance for the analyzers and common reagents that are used alongside the assay kits. The company has now completed the declaration of conformity to the European IVD regulation (IVDR) for these analyzers and common reagents. With these regulatory milestones achieved, Sysmex is set to expand the market for the assay kits in medical institutions across Europe from January 2024 onwards.
The assay kits, diagnostic reagents that measure Alzheimer’s disease-related blood biomarkers, are the first to meet the requirements for CE-IVD marking in Europe for use on a fully automated immunoassay platform. They allow for minimally invasive, affordable testing with just a small amount of blood for patients suspected of having Aβ accumulation in the brain. In addition, the testing process can be done easily and rapidly (in just 17 minutes for measurement) using Sysmex’s HISCL-Series analyzers. There is expected to be a growing demand for the assay kits because they can help ensure the proper use and clinical implementation of Alzheimer’s disease-modifying drugs, which have been actively developed in recent years.
Going forward, Sysmex will work on expanding testing parameters including the assay kits in order to accelerate the development of its immunochemistry testing business in Europe.
Sysmex will continue its efforts towards the development and diffusion of high-value diagnostic technologies to improve people’s lifetime healthcare journey.2
February 15, 2016 news release: “Sysmex and Eisai Enter Comprehensive Agreement to Create Next-generation Diagnostic Reagents in the Field of Dementia”
June 27, 2022 news release: “Completion of Declaration of Conformity to the European IVD Directive for an Assay Kit that Measures Plasma Amyloid Beta (Aβ) Using the Automated Immunoassay System HISCL™-5000/HISCL™-800”
  June 22, 2023 news release: “Sysmex Launches an Assay Kit to Identify Amyloid Beta (Aβ) Accumulation in the Brain, a Cause of Alzheimer’s Disease, Using a Small Amount of Blood”
August 29, 2023 news release: “Sysmex Begins Supplying Reagents for U.S. Based Laboratory Developed Test (LDT) Measuring Amyloid Beta (Aβ) in Blood”

Laboratory Developed Test: LDT
A laboratory developed test (LDT) is a type of in vitro diagnostic test that is designed, manufactured, and used within a single laboratory.
 2. Sysmex promotes the concept of a “healthcare journey.” We view the various healthcare-related events a person experiences throughout their lives (life stages), along with the corresponding processes these involve (such as treatment at healthcare institutions), as a “journey”. Through various collaborations, we aim to offer new value, to make each individual’s healthcare journey better, and to grow as an essential presence in society.

About Sysmex Corporation

Sysmex Corporation, headquartered in Kobe, Japan, is a global leader in in vitro diagnostics. Since its foundation in 1968, Sysmex has focused on diagnostics as the core of its business, and today, it supports the health of people in over 190 countries and regions worldwide. Sysmex continues to innovate in diagnostics, and to collaboratively create unique values in the areas of personalized medicine and novel treatments, under its long-term vision of "Together for a better healthcare journey." Through its unique technology, solutions, and co-creation with various partners, Sysmex delivers new value and addresses the universal desire of people to live longer and healthier lives. 
For more information about Sysmex, please visit


  • The purpose of this news release is to communicate our business activities to our stakeholders. It may or may not include information about Sysmex's products or their research and development, but this is not intended for promotion, advertising or medical advice. The information contained in this news release is current as of the date of the announcement but may be subject to change without prior notice.

Back to "News"